SPOTLIGHT: Sorafenib application completed

Bayer and Onyx Pharmaceuticals have supplied the last piece of information to the FDA to support their marketing application for Sorafenib to treat advanced kidney disease. They hope to begin marketing the drug in the first half of 2006. Report

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.